Roche: DMLA treatment proves non-inferiority
(CercleFinance.com) - Four phase III clinical studies have demonstrated the efficacy of faricimab, Roche's investigational treatment for neovascular (wet) age-related macular degeneration (AMD), a major cause of blindness in people over 60 years of age.
The studies - which were designed to investigate the efficacy and safety of faricimab compared to aflibercept, the reference treatment for the disease - showed a result of non-inferiority, Roche said in a statement.
While current therapies for neovascular AMD are effective, they are cumbersome treatments requiring frequent visits to clinics for injections.
Roche's faricimab - an antibody specifically designed for the eye - is advantageus in that it can be given every four months, compared to an injection every two months for Bayer's aflibercept.
The Roche share is almost keeping afloat in a flat Swiss market.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The studies - which were designed to investigate the efficacy and safety of faricimab compared to aflibercept, the reference treatment for the disease - showed a result of non-inferiority, Roche said in a statement.
While current therapies for neovascular AMD are effective, they are cumbersome treatments requiring frequent visits to clinics for injections.
Roche's faricimab - an antibody specifically designed for the eye - is advantageus in that it can be given every four months, compared to an injection every two months for Bayer's aflibercept.
The Roche share is almost keeping afloat in a flat Swiss market.
Copyright (c) 2021 CercleFinance.com. All rights reserved.